Valdospan GmbH is a biotechnology company, which develops life-changing medicine for the therapy of virally induced life-threatening infectious diseases and deadly forms of cancer.

The required research is based on company-developed exploration platforms. These innovative technologies allow the development of pharmacologically highly reactive substances. The potent drugs lead to targeted degradation of viral proteins to cure the disease.

Valdospan acts as main research facility in the strong alliance of RDP-Pharma.